NASDAQ:GOVX GeoVax Labs (GOVX) Stock Price, News & Analysis $1.01 -0.01 (-0.98%) As of 05/23/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeoVax Labs Stock (NASDAQ:GOVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GeoVax Labs alerts:Sign Up Key Stats Today's Range$0.97▼$1.0250-Day Range$0.76▼$1.4152-Week Range$0.73▼$11.18Volume116,853 shsAverage Volume527,672 shsMarket Capitalization$15.35 millionP/E RatioN/ADividend YieldN/APrice Target$11.10Consensus RatingBuy Company OverviewGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Read More… GeoVax Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreGOVX MarketRank™: GeoVax Labs scored higher than 56% of companies evaluated by MarketBeat, and ranked 446th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingGeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGeoVax Labs has only been the subject of 3 research reports in the past 90 days.Read more about GeoVax Labs' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeoVax Labs are expected to grow in the coming year, from ($4.49) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeoVax Labs is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeoVax Labs is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GeoVax Labs' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.89% of the outstanding shares of GeoVax Labs have been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently increased by 8.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.89% of the outstanding shares of GeoVax Labs have been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently increased by 8.38%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News SentimentN/A News SentimentGeoVax Labs has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for GeoVax Labs this week, compared to 1 article on an average week.Search Interest19 people have searched for GOVX on MarketBeat in the last 30 days. This is an increase of 111% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $33,884.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of GeoVax Labs is held by insiders.Percentage Held by InstitutionsOnly 6.09% of the stock of GeoVax Labs is held by institutions.Read more about GeoVax Labs' insider trading history. Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address GOVX Stock News HeadlinesGeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense InnovationMay 21 at 5:55 PM | finance.yahoo.comGeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine ProductionMay 6, 2025 | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 24, 2025 | Paradigm Press (Ad)Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and Baxter International (BAX)May 5, 2025 | theglobeandmail.comGeovax highlights progress on mpox vaccine and COVID-19 trial advancementsMay 2, 2025 | msn.comGeoVax Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 2, 2025 | finance.yahoo.comGeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comGeoVax Responds to Detection of Clade I Mpox in North Carolina WastewaterApril 25, 2025 | theglobeandmail.comSee More Headlines GOVX Stock Analysis - Frequently Asked Questions How have GOVX shares performed this year? GeoVax Labs' stock was trading at $2.47 at the start of the year. Since then, GOVX stock has decreased by 59.1% and is now trading at $1.01. View the best growth stocks for 2025 here. How were GeoVax Labs' earnings last quarter? GeoVax Labs, Inc. (NASDAQ:GOVX) issued its earnings results on Thursday, May, 1st. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.14. The business had revenue of $1.64 million for the quarter, compared to the consensus estimate of $0.75 million. Read the conference call transcript. When did GeoVax Labs' stock split? GeoVax Labs's stock reverse split before market open on Wednesday, January 31st 2024. The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are GeoVax Labs' major shareholders? GeoVax Labs' top institutional investors include Armistice Capital LLC (4.36%) and Jane Street Group LLC (0.17%). Insiders that own company stock include David A Dodd, Mark Reynolds, John N Spencer Jr, John W Sharkey, Randal D Chase and Kelly T Jr Mckee. View institutional ownership trends. How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeoVax Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeoVax Labs investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Ovid Therapeutics (OVID). Company Calendar Last Earnings5/01/2025Today5/24/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOVX CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$11.10 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+999.0%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,970,000.00 Net MarginsN/A Pretax Margin-787.09% Return on Equity-809.87% Return on Assets-349.34% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual Sales$5.59 million Price / Sales2.74 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.31Miscellaneous Outstanding Shares15,194,000Free Float8,898,000Market Cap$15.35 million OptionableNot Optionable Beta3.47 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:GOVX) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Hidden Energy Source Backed by Billionaires Why Billionaires Have Set Their Sights on the Utah Desert Something strange is happening near the Wah Wah ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.